Global Next-Generation Antibody Therapeutics Market: Market Segments: By Therapeutic Area (Oncology Autoimmune/Inflammatory); By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins & Biosimilar Antibody Products);and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030
December 2020
179
About the Report
About the Report
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
- Row Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
- In June 2019, Xencor has initiated the first dose in patients in phase I clinical trial for XmAb22841, a bispecific antibody that targets CTLA-4 and LAG-3 receptor inhibitors for the treatment of advanced solid tumors. If successful, it will change the treatment landscape of patients suffering from advanced solid tumors throughout the world
- In December 2018, Seattle Genetics, Inc in collaboration with Takeda Pharmaceutical Company Limited has reported in the press release that the ECHELON-2 phase III clinical trial demonstrated clinically meaningful outcomes of brentuximab vedotin in combination with CHP (cyclophosphamide, doxorubicin, and prednisone) for the treatment of CD30-Expressing Peripheral T-cell lymphomas. If SUCCESSFUL, it will bring a potential new treatment option to patients suffering from peripheral T-cell lymphomas across the globe.
-
Bristol-Myers Squibb
-
Company Overview
-
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Bayer
- Takeda Pharmaceuticals
- Biogen
- Seattle Genetics
- ImmunoGen
- Kyowa Hakko Kirin
- Xencor
- Dyax Corp
- By Therapeutic Area:
- Oncology
- Autoimmune/Inflammatory
- By Technology:
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies
- Fc-engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
- Next-generation antibody therapeutics Market Dynamics
- Next-generation antibody therapeutics Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
Products
Table of Contents
Table of Contents
Contents
- Executive Summary
- Global Next-Generation Antibody Therapeutics Market
- Product Overview
- Market Definition
- Segmentation
- Assumptions and Acronyms
- Research Methodology
- Research Objectives
- Primary Research
- Secondary Research
- Forecast Model
- Market Size Estimation
- Average Pricing Analysis
- Macro-Economic Indicators
- Market Dynamics
- Growth Drivers
- Restraints
- Opportunity
- Trends
- Correlation & Regression Analysis
- Correlation Matrix
- Regression Matrix
- Recent Development, Policies & Regulatory Landscape
- Risk Analysis
- Demand Risk Analysis
- Supply Risk Analysis
- Global Next-Generation Antibody Therapeutics Market Analysis
- Porters Five Forces
- Threat of New Entrants
- Bargaining Power of Suppliers
- Threat of Substitutes
- Rivalry
- PEST Analysis
- Political
- Economic
- Social
- Technological
- Porters Five Forces
- Global Next-Generation Antibody Therapeutics Market
- Market Size & forecast, 2019A-2030F
- By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Market Size & forecast, 2019A-2030F
- Global Next-Generation Antibody Therapeutics Market: Market Segmentation
- By Regions
- North America: (U.S. and Canada) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- By Regions
12.3. By Technology: Market Share (2020-2030F)
12.3.1. Antibody-Drug Conjugates (ADCs), By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.2. Bispecific Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.3. Antibody Fragments and Antibody-like Proteins, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.4. Fc-engineered Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.5. Biosimilar Antibody Products, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Company Profile
- Hoffmann-La Roche Ltd.
- Company Overview
- Company Total Revenue (Financials)
- Market Potential
- Global Presence
- Key Performance Indicators
- SWOT Analysis
- Product Launch
- Kyowa Hakko Kirin Co. Ltd.
- Seattle Genetics Inc.
- ImmunoGen Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Amgen Inc
- Biogen
- Xencor Inc
- Other Prominent Players
- Hoffmann-La Roche Ltd.
- Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.